237 related articles for article (PubMed ID: 11416715)
1. Comparison of the effectiveness of non-nucleoside reverse transcriptase inhibitor-containing and protease inhibitor-containing regimens using observational databases.
Ghani AC; Henley WE; Donnelly CA; Mayer S; Anderson RM
AIDS; 2001 Jun; 15(9):1133-42. PubMed ID: 11416715
[TBL] [Abstract][Full Text] [Related]
2. Abacavir-based triple nucleoside regimens for maintenance therapy in patients with HIV.
Cruciani M; Mengoli C; Serpelloni G; Parisi SG; Malena M; Bosco O
Cochrane Database Syst Rev; 2013 Jun; (6):CD008270. PubMed ID: 23740608
[TBL] [Abstract][Full Text] [Related]
3. Response to first protease inhibitor- and efavirenz-containing antiretroviral combination therapy. The Swiss HIV Cohort Study.
Friedl AC; Ledergerber B; Flepp M; Hirschel B; Telenti A; Furrer H; Bucher HC; Bernasconi E; Weber R;
AIDS; 2001 Sep; 15(14):1793-800. PubMed ID: 11579241
[TBL] [Abstract][Full Text] [Related]
4. Dual vs single protease inhibitor therapy following antiretroviral treatment failure: a randomized trial.
Hammer SM; Vaida F; Bennett KK; Holohan MK; Sheiner L; Eron JJ; Wheat LJ; Mitsuyasu RT; Gulick RM; Valentine FT; Aberg JA; Rogers MD; Karol CN; Saah AJ; Lewis RH; Bessen LJ; Brosgart C; DeGruttola V; Mellors JW;
JAMA; 2002 Jul; 288(2):169-80. PubMed ID: 12095381
[TBL] [Abstract][Full Text] [Related]
5. A comparison of three highly active antiretroviral treatment strategies consisting of non-nucleoside reverse transcriptase inhibitors, protease inhibitors, or both in the presence of nucleoside reverse transcriptase inhibitors as initial therapy (CPCRA 058 FIRST Study): a long-term randomised trial.
MacArthur RD; Novak RM; Peng G; Chen L; Xiang Y; Hullsiek KH; Kozal MJ; van den Berg-Wolf M; Henely C; Schmetter B; Dehlinger M; ;
Lancet; 2006 Dec; 368(9553):2125-35. PubMed ID: 17174704
[TBL] [Abstract][Full Text] [Related]
6. Estimated average annual rate of change of CD4(+) T-cell counts in patients on combination antiretroviral therapy.
Mocroft A; Phillips AN; Ledergerber B; Smith C; Bogner JR; Lacombe K; Wiercinska-Drapalo A; Reiss P; Kirk O; Lundgren JD;
Antivir Ther; 2010; 15(4):563-70. PubMed ID: 20587849
[TBL] [Abstract][Full Text] [Related]
7. Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.
Siripassorn K; Manosuthi W; Chottanapund S; Pakdee A; Sabaitae S; Prasithsirikul W; Tunthanathip P; Ruxrungtham K;
AIDS Res Hum Retroviruses; 2010 Feb; 26(2):139-48. PubMed ID: 20156097
[TBL] [Abstract][Full Text] [Related]
8. Triple nucleoside reverse transcriptase inhibitor- vs. nonnucleoside reverse transcriptase inhibitor-containing regimens as first-line therapy: efficacy and durability in a prospective cohort of French HIV-infected patients.
Cuzin L; Pugliese P; Bugnon F; Delpierre C; Cua E; Billaud E; Massip P; Raffi F; Dellamonica P
HIV Med; 2005 Nov; 6(6):388-95. PubMed ID: 16268820
[TBL] [Abstract][Full Text] [Related]
9. Provider bias in the selection of non-nucleoside reverse transcriptase inhibitor and protease inhibitor-based highly active antiretroviral therapy and HIV treatment outcomes in observational studies.
Wood E; Hogg RS; Heath KV; de la Rosa R; Lee N; Yip B; O'Shaughnessy MV; Montaner JS
AIDS; 2003 Dec; 17(18):2629-34. PubMed ID: 14685057
[TBL] [Abstract][Full Text] [Related]
10. Intermittent episodes of detectable HIV viremia in patients receiving nonnucleoside reverse-transcriptase inhibitor-based or protease inhibitor-based highly active antiretroviral therapy regimens are equivalent in incidence and prognosis.
Sungkanuparph S; Overton ET; Seyfried W; Groger RK; Fraser VJ; Powderly WG
Clin Infect Dis; 2005 Nov; 41(9):1326-32. PubMed ID: 16206110
[TBL] [Abstract][Full Text] [Related]
11. HIV RNA and CD4 cell count response to protease inhibitor therapy in an urban AIDS clinic: response to both initial and salvage therapy.
Deeks SG; Hecht FM; Swanson M; Elbeik T; Loftus R; Cohen PT; Grant RM
AIDS; 1999 Apr; 13(6):F35-43. PubMed ID: 10397555
[TBL] [Abstract][Full Text] [Related]
12. Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients.
Phillips AN; Pradier C; Lazzarin A; Clotet B; Goebel FD; Hermans P; Antunes F; Ledergerber B; Kirk O; Lundgren JD;
AIDS; 2001 Dec; 15(18):2385-95. PubMed ID: 11740189
[TBL] [Abstract][Full Text] [Related]
13. Restoration of human immunodeficiency virus-1-specific responses in patients changing from protease to non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
Sullivan AK; Burton CT; Nelson MR; Moyle G; Mandalia S; Gotch FM; Gazzard BG; Imami N
Scand J Immunol; 2003 Jun; 57(6):600-7. PubMed ID: 12791099
[TBL] [Abstract][Full Text] [Related]
14. Comparison of single and boosted protease inhibitor versus nonnucleoside reverse transcriptase inhibitor-containing cART regimens in antiretroviral-naïve patients starting cART after January 1, 2000.
Mocroft ; Horban ; Clumeck ; Stellbrink ; Monforte dA; Zilmer ; Kirk ; Gatell ; Phillips ; Lundgren ;
HIV Clin Trials; 2006; 7(6):271-84. PubMed ID: 17208897
[TBL] [Abstract][Full Text] [Related]
15. Switch from a first virologically effective protease inhibitor-containing regimen to a regimen containing efavirenz, nevirapine or abacavir.
Abgrall S; Yeni PG; Bouchaud O; Costagliola D;
AIDS; 2006 Oct; 20(16):2099-106. PubMed ID: 17053356
[TBL] [Abstract][Full Text] [Related]
16. Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen.
Gianotti N; Galli L; Galizzi N; Ripa M; Andolina A; Nozza S; Spagnuolo V; Poli A; Lazzarin A; Castagna A
Int J Antimicrob Agents; 2018 Oct; 52(4):492-499. PubMed ID: 30009958
[TBL] [Abstract][Full Text] [Related]
17. Two-year outcomes of children on non-nucleoside reverse transcriptase inhibitor and protease inhibitor regimens in a South African pediatric antiretroviral program.
Jaspan HB; Berrisford AE; Boulle AM
Pediatr Infect Dis J; 2008 Nov; 27(11):993-8. PubMed ID: 18818556
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, safety, and adherence with a twice-daily combination lamivudine/zidovudine tablet formulation, plus a protease inhibitor, in HIV infection.
Eron JJ; Yetzer ES; Ruane PJ; Becker S; Sawyer GA; Fisher RL; Tolson JM; Shaefer MS
AIDS; 2000 Apr; 14(6):671-81. PubMed ID: 10807190
[TBL] [Abstract][Full Text] [Related]
19. Switch to efavirenz in a protease inhibitor-containing regimen.
Knechten H; Stürner KH; Höhn C; Braun P
HIV Clin Trials; 2001; 2(3):200-4. PubMed ID: 11590528
[TBL] [Abstract][Full Text] [Related]
20. NNRTI plus PI combinations in the perspective of nucleoside-sparing or nucleoside-failing antiretroviral regimens.
Joly V; Descamps D; Yeni P
AIDS Rev; 2002; 4(3):128-39. PubMed ID: 12416447
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
